Complete Story
 

09/05/2012

FDA approves XTANDI (enzalutamide)

The FDA approved Medivation and Astellas' Xtandi (enzalutamide) after a priority review for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who previously received chemotherapy, READ MORE

link to the product website:  www.XtandiHCP.com